Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma - Scorecard - MDSpire
Clinical Scorecard: Influence of Lymphocyte Dynamics and Immune Profile on Outcomes of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma
At a Glance
Category
Detail
Condition
Relapsed/Refractory Multiple Myeloma
Key Mechanisms
Efficacy of bispecific antibodies depends on immune-compartment fitness and lymphocyte dynamics.
Target Population
Patients with relapsed/refractory multiple myeloma receiving bispecific antibody treatment.
Care Setting
Multiple US academic cancer centers.
Key Highlights
Overall response rates to bispecific antibodies reach 70%.
Baseline lymphocyte count does not predict treatment response.
Lymphocyte subset dynamics correlate with progression-free survival and overall survival.
Higher CD56 NK-cell counts observed in responders.
Exploratory score based on lymphocyte subsets predicts outcomes.
Guideline-Based Recommendations
Diagnosis
Evaluate response using International Myeloma Working Group criteria.
Management
Monitor lymphocyte dynamics during bispecific antibody treatment.
Monitoring & Follow-up
Assess absolute lymphocyte count and lymphocyte subset composition at baseline and during treatment.
Risks
High-risk cytogenetic abnormalities associated with inferior response.
Patient & Prescribing Data
303 patients with relapsed/refractory multiple myeloma.
Median age 70 years; 52% male; median baseline ALC 0.91 × 10³/µL.
Clinical Best Practices
Consider lymphocyte subset trajectories when evaluating treatment efficacy.
Utilize exploratory scoring system for predicting patient outcomes.
